Biana Godin Vilentchouk, Ph.D., M.Sc.Pharm.
|B.Pharm.||The Hebrew University of Jerusalem, Israel|
|M.Sc.Pharm.||The Hebrew University of Jerusalem, Israel|
|Ph.D.||The Hebrew University of Jerusalem, Israel (Pharmaceutical Sciences)|
The Hebrew University if Jerusalem, Israel (Pharmaceutics)
University of Texas Health Science Center at Houston, TX (Nanomedicine)
Dr. Biana Godin Vilentchouk earned her Ph.D. in Pharmaceutical Sciences from the Hebrew University of Jerusalem in 2006. During her PhD studies, Dr. Godin Vilentchouk focused on designing a non-invasive treatment for the hard-to-treat skin deep infections and on nasal delivery of proteins. She was recruited as a Postdoctoral trainee in the field of Cancer Nanotechnology to the research team of Dr. Mauro Ferrari at the University of Texas Health Sciences Center. Her postdoctoral research focused on injectable multistage nanovectors (MSVs) for cancer treatment and imaging. Her work provided insightful understanding of the interactions of MSVs with immune cells in vivo and in vitro, biocompatibility of MSV, effect of geometry and targeting moieties on MSV biodistribution, and evaluation of MSV systems as near-infra red and MRI imaging agents. During the three years of her postdoctoral research, Dr. Godin Vilentchouk published numerous book chapters, and peer-reviewed articles and reviews in top journals including Nature Nanotechnology and Cancer Research. She also received awards for her work at international conferences. In October 2010, Dr. Biana Godin Vilentchouk joined the Department of Nanomedicine at TMHRI.
Dr. Godin Vilentchouk's research focuses primarily on the following four areas:
The main objective of these studies is to provide innovative approaches to cancer treatment and diagnosis. Dr. Godin Vilentchouk is one of the key team members on two multicenter multi-investigator NIH National Cancer Institute grants: Physical Science in Oncology and Center for Cancer Nanotechnology Excellence. She is a PI on TATRC/DoD seed-grant and two NIH pilot projects. Dr. Godin Vilentchouk's research interests also include nanomedicine applications in cardiology and infectious diseases.
Nanomedicine, cancer, physical sciences in oncology, nanocarrier biocompatibility, biodistribution
Ananta JS*, Godin B*, Sethi R, Moriggi L, Liu X, Serda RE, Krishnamurthy R, Muthupillai R, Helm L, Ferrari M, Wilson LJ, Decuzzi P. Geometrical confinement of Gd-based agents in nanoporous particles enhances T1 contrast. Nat Nanotechnol. 2010 Nov;5(11):815-21. PMID: 20972435; *equal contribution
Tasciotti E*, Godin B*, Martinez JO, Chiappini C, Bhavane R, Liu X, Ferrari M. A near-infrared imaging method for the in-vivo assessment of the biodistribution of porous silicon particles. Mol Imaging, 2011, 10(1):56-68. PMID: 21303615; *equal contribution
Refuerzo JS*, Godin B*, Bishop K, Srinivasan S, Shah S, Ramin SM, Ferrari M. Size of the nanovectors determines the transplacental passage in pregnancy: study in rats. 2011 Apr 7. [Epub ahead of print], PMID: 21481834; *equal contribution.
Godin B, Gu J, Serda RE, Bhavane R, Tasciotti E, Chiappini C, Liu X, Tanaka T, Decuzzi P, Ferrari M. Tailoring the degradation kinetics of mesoporous silicon structures through PEGylation. J Biomed Mater Res A. 2010 Sep 15;94(4):1236-43. PMID: 20694990
Serda RE, Mack A, van de Ven A, Ferrati S, Dunner K, Godin B, Chiappini C, Landry M, Brousseau L, Liu X, Bean AJ, Ferrari M. Logic-embedded vectors for intracellular partitioning, endosomal escape and exocytosis of nanoparticles. Small. 2010 Dec 6;6(23):2691-700. PMID: 20957619
Godin B, Driessen WH, Proneth B, Lee S-Y, Srinivasan S, Rumbaut R, Arap W, Pasqualini R, Ferrari M, Decuzzi P. An integrated approach for the rational design of nanovectors for biomedical imaging and therapy. Adv Genet. 2010;69:31-64. PMID: 20807601
Tanaka T, Mangala LS, Vivas-Mejia PE, Nieves-Alicea R, Mann AP, Mora E, Han H-D, Shahzad MMK, Liu X, Bhavane R, Gu J, Fakhoury JR, Chiappini C, Lu C, Matsuo K, Godin B, Stone RL, Nick AM, Lopez-Berestein G, Sood AK, Ferrari M. Sustained siRNA delivery by mesoporous silicon particles. Cancer Res. 2010 May 1;70(9):3687-96.PMID: 20430760
Godin B, Sakamoto JH, Serda RE, Grattoni A, Boumarini A, Ferrari M. Emerging applications of nanomedicine for therapy and diagnosis of cardiovascular diseases. Trends Pharmacol Sci. 2010 May;31(5):199-205. Epub 2010 Feb 19. PMID: 20172613
Tanaka T*, Godin B*, Bhavane R, Nieves RA, Gu J, Liu X, Chiappini C, Fakhoury J, Amra S, Ewing A, Li Q, Fidler IJ, Ferrari M. In vivo evaluation of safety of nanoporous silicon carriers following single and multiple dose intravenous administrations in mice. Int J Pharm. 2010 Dec 15;402(1-2):190-7. PMID: 20883755; *equal contribution
Serda RE, Mack A, Pulikkathara M, Zaske AM, Chiappini C, Fakhoury J, Webb D, Godin B, Conyers JL, Liu X, Bankson JA, Ferrari M. Cellular association and assembly of a multi-stage delivery system. Small. 2010 Jul 13. PMID: 20629053
Serda R, Godin B, Tasciotti E, Blanco E, Ferrari M. Multi-stage delivery nano-particle systems for therapeutic applications. Biochim Biophys Acta. 2010 May 21. PMID: 20493927
Sakamoto J, Van de Ven A, Godin B, Blanco E, Serda RE, Grattoni A, Ziemys A, Hu Y, Ranganathan S, De Rosa E, Martinez J, Smid CA, Buchanan RM, Lee SY, Srinivasan S, Meyn A, Tasciotti E, Liu X, Decuzzi P, Ferrari M. Enabling individualized therapy through nanotechnology. Pharmacol Res. 2010 Aug;62(2):57-89. PMID: 20045055